3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Nasopharyngeal Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
59
Nivolumab
34
Cyclophosphamide
21
fludarabine
15
Paclitaxel
12
Ipilimumab
12
atezolizumab
11
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
Carboplatin
10
Docetaxel
9
Cisplatin
9
Gemcitabine
8
Biopsy
8
durvalumab
7
aldesleukin
7
Radiosurgery
7
Interleukin-2
7
Bevacizumab
7
cemiplimab
6
Pemetrexed
6
fludarabine phosphate
5
avelumab
5
Radiotherapy
5
Drug Therapy
5
spartalizumab
4
epacadostat
4
enzalutamide
4
Taxes
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Nicotine Replacement Therapy
×
Gastrointestinal
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled